Polatuzumab vedotin
- Generic Name
- Polatuzumab vedotin
- Brand Names
- Polivy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1313206-42-6
- Unique Ingredient Identifier
- KG6VO684Z6
- Background
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrul...
- Indication
Polatuzumab vedotin is used in combination with bendamustine and rituximab to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. In Canada, this indication is approved for patients who are not eligible for autologous stem cell transplant and have received at least one p...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma, High-grade B Cell Lymphoma (HGBCL), Large B Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT02600897
- Locations
- ๐ฌ๐ง
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom
๐ฌ๐งMaidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom
๐ฌ๐งBarking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, United Kingdom
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01992653
- Locations
- ๐ซ๐ท
Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France
๐บ๐ธBanner MD Anderson Cancer Center, Greeley, Colorado, United States
๐บ๐ธThe University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01691898
- Locations
- ๐ฎ๐น
Azienda Ospedale San Giovanni, Torino, Piemonte, Italy
๐บ๐ธTexas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States
๐จ๐ฆMcGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT01290549
- Locations
- ๐บ๐ธ
M.D Anderson Cancer Center; Oncology, Houston, Texas, United States
๐บ๐ธFlorida Cancer Specialists; Sarasota, Sarasota, Florida, United States
๐ซ๐ทCentre Hospitalier Regional Universitaire de Lille, Lille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.